|Bid||0.00 x 800|
|Ask||2.65 x 1200|
|Day's Range||2.08 - 2.25|
|52 Week Range||1.68 - 5.10|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.25|
VBI Vaccines Inc. (VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced that, based on the quality and scientific content, the company’s late-breaker abstract, “An Enveloped Virus-like Particle (eVLP) Cytomegalovirus (CMV) Vaccine is Immunogenic and Safe: Results of a First-in-Humans Study,” has been selected for oral presentation at IDWeek 2018, in San Francisco, CA, on October 6, 2018. Dr. Soren Gantt, M.D., Ph.D., MPH, Associate Professor with the Division of Infectious Disease in the Department of Pediatrics, University British Columbia Faculty of Medicine, BC Children’s Hospital, and an investigator of the VBI-1501 Phase I study, will deliver the oral presentation. Dr. Gantt’s presentation will discuss the complete safety and immunogenicity dataset from the Phase 1, randomized, placebo-controlled clinical study evaluating the company’s prophylactic CMV vaccine candidate, VBI-1501.
CAMBRIDGE, Mass., Sept. 27, 2018-- VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff ...
CAMBRIDGE, Mass., Sept. 26, 2018-- VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation ...
VBI Vaccines Inc. (VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent GBM. The DSMB reviewed the complete safety data from the fully enrolled, intermediate-dose patient cohort, and unanimously recommended the continuation of the study without modification.
VBI Vaccines Inc. (VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12, 2018, written by Gali Weinreb (the “Article”) alleging that VBI failed to meet its responsibilities of disclosure regarding a court case in Israel. Those allegations are not only false, but a gross mischaracterization of the facts. VBI holds itself to the highest standards of integrity and has been fully-compliant with disclosure requirements and regulations.
VBI Vaccines Inc. (VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as Chief Financial Officer and Head of Business Development, effective immediately. Mr. McNulty is an accomplished financial executive in the biopharmaceutical and medical device field, with a strong background in licensing transactions, capital markets and financing strategy, and public company corporate finance. “We are delighted to have Chris join VBI during this very exciting time in the company’s growth trajectory,” said Jeff Baxter, VBI’s President and CEO.
VBI Vaccines Inc. (VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston, MA, on Wednesday, August 8, 2018, at 9:30 a.m. EDT. A live webcast of the presentation and a subsequent replay may be accessed by visiting the Investors page of VBI’s website at: www.vbivaccines.com/investors/events-presentations/. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.
NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus ...
--Pivotal Phase 3 program for Sci-B-Vac ® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019--. --Positive safety and immunogenicity data from Phase 1 study of VBI-1501 ...
LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on VBI Vaccines Inc. (NASDAQ: VBIV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VBIV as the Company's latest news hit the wire. On May 10, 2018, the commercial-stage biopharmaceutical Company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology, reported positive results from the randomized, placebo-controlled Phase-1 study of VBI-1501. Active-Investors.com is currently working on the research report for Adaptimmune Therapeutics PLC (NASDAQ: ADAP), which also belongs to the Healthcare sector as the Company VBI Vaccines.
Stock Monitor: KemPharm Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on VBI Vaccines Inc. (NASDAQ: VBIV ). If you want ...
In case you missed it, here are some of Benzinga's top stories from Thursday, March 15th, 2018. Energy Stocks And ETFs Struggle For energy investors, the weakness in energy stocks and ETFs that characterized ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)